Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on the development of immunologic based therapies for the prevention and treatment of disease, announced its entry into a definitive agreement with a leading health care-focused institutional investor. Under the agreement, the company agreed to sell 1,293,126 shares of common stock, each at a gross purchase price of $3.00. Revelation additionally agreed to issue to the investor unregistered warrants to purchase up to 2,586,667 shares (the “common warrants”), as well as unregistered pre-funded warrants to purchase up to 1,293,541 shares (the “pre-funded warrants” and together with the common warrants, the “warrants”) in a concurrent private placement. The common warrants, with an exercise price of $3.29 per share, will become exercisable in six months after their date of issuance and will expire five and a half years from their date of issuance. The pre-funded warrants have been funded to the amount of $3.00 with $0.0001 payable on exercise. Roth Capital Partners acted as sole placement agent for the offering, which closed on Jan. 25, 2022.
To view the full press release, visit https://ibn.fm/uROIE
About Revelation Biosciences Inc.
Revelation Biosciences is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. For more information, please visit www.RevBiosciences.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
